Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy

被引:1
|
作者
Laliscia, Concetta [1 ]
Coccia, Natalina [1 ]
Fuentes, Taiusha [1 ]
Perrone, Franco [2 ]
Paiar, Fabiola [1 ]
机构
[1] Univ Pisa, Dept New Technol & Translat Res, Div Radiat Oncol, Via Roma 67, I-56127 Pisa, Italy
[2] Univ Pisa, Med Phys Dept, Pisa, Italy
关键词
non-melanoma skin cancer; brachytherapy; Valencia applicator; BASAL-CELL CARCINOMA; STANDARDIZED SURFACE APPLICATORS; RADIATION-THERAPY; HDR BRACHYTHERAPY; GUIDELINES; RECURRENCE;
D O I
10.5114/jcb.2021.112111
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this retrospective study was to analyze tumor control, toxicity, and aesthetic outcome of patients affected by non-melanoma skin cancer (NMSC) and treated with iridium-192 (192Ir) high-dose-rate (HDR) brachytherapy (BT) using Valencia applicators at the Division of Radiotherapy, University of Pisa. Material and methods: From June 2015 to December 2020, 95 NMSC patients, including 61.5% basal cell carcinoma and 38.5% squamous cell carcinoma patients, with median age of 83 years (range, 32-96 years) were treated. In total, 182 lesions with a diameter <= 25 mm (median, 12 mm) and a depth <= 4 mm, located in scalp (19.2%), face (20.9%), chest (8.8%), nose (16.5%), ear (15.4%), and extremities (19.2%) were analyzed. All lesions were treated with 192Ir-based HDR afterloader using Valencia applicators. 105 lesions (57.7%) were treated with applicator of 20 mm and 77 lesions (42.3%) with applicator of 30 mm in diameter, depending on the size of lesions. Prescribed dose was 40 Gy in 8 fractions (5 Gy/fraction) delivered 2-3 times a week. Biological effective dose (BED) was approximate to 60 Gy. Results: The median follow-up was 14 months (range, 3-59 months). The 2-year local control rate was 96%. According to common terminology criteria for adverse events (CTCAE v. 5.0), G1-G2 acute toxicities included dermatitis (22.0%) and pain (8.2%). The most common G1 late toxicities were hypopigmentation (27.5%) and fibrosis (8.2%), and G2 late toxicity included ulceration (0.5%). No G3 or higher acute or late toxicities were reported. Excellent cosmetic results were observed in 77.5% of the lesions, with one only (0.5%) reported as a poor cosmetic result (ulceration refractory to therapy). Conclusions: HDR-BT using Valencia applicators is a safe, effective, and well-tolerated treatment modality for NMSC, and can be considered a good alternative for treatment, especially in elderly patients who are often unfit for surgery.
引用
收藏
页码:615 / 619
页数:5
相关论文
共 50 条
  • [31] Clinical Results of Iridium-192 High Dose Rate Brachytherapy with External Beam Radiotherapy
    Nohara, Takahiro
    Mizokami, Atsushi
    Kumano, Tomoyasu
    Shigehara, Kazuyoshi
    Konaka, Hiroyuki
    Yoshifumi, Kadono
    Yasuhide, Kitagawa
    Izumi, Kouji
    Narimoto, Kazutaka
    Namiki, Mikio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) : 677 - 683
  • [32] Radiobiological comparison between Cobalt-60 and Iridium-192 high-dose-rate brachytherapy sources: Part I-cervical cancer
    Dayyani, Mahdieh
    Hoseinian-Azghadi, Elie
    Miri-Hakimabad, Hashem
    Rafat-Motavalli, Laleh
    Abdollahi, Sara
    Mohammadi, Najmeh
    MEDICAL PHYSICS, 2021, 48 (10) : 6213 - 6225
  • [33] Dosimetric comparison of Acuros™ BV and AAPM TG-43 formalism for interstitial iridium-192 high-dose-rate brachytherapy
    Roussakis, Yiannis
    Antorkas, Georgios
    Georgiou, Leonidas
    Strouthos, Iosif
    Karagiannis, Efstratios
    Zamboglou, Constantinos
    Ferentinos, Konstantinos
    Zamboglou, Nikolaos
    Anagnostopoulos, Georgios
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2024, 16 (03) : 211 - 218
  • [34] Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer
    Hiratsuka, J
    Jo, Y
    Yoshida, K
    Nagase, N
    Fujisawa, M
    Imajo, Y
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (03): : 684 - 690
  • [35] Dosimetric Considerations for Ytterbium-169, Selenium-75, and Iridium-192 Radioisotopes in High-Dose-Rate Endorectal Brachytherapy
    Shoemaker, Tristan
    Te Vuong
    Glickman, Harry
    Kaifi, Samar
    Famulari, Gabriel
    Enger, Shirin A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (04): : 875 - 883
  • [36] Dosimetric characterization of the M-15 high-dose-rate Iridium-192 brachytherapy source using the AAPM and ESTRO formalism
    Minh-Tri Ho Thanh
    Munro, John J., III
    Medich, David C.
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2015, 16 (03): : 305 - 317
  • [37] Non-melanoma Skin Cancer Treated by Contact High-dose-rate Radiotherapy (Brachytherapy) : A Mono-institutional Series and Literature Review
    Tagliaferri, Luca
    Ciardo, Francesco Giuseppe
    Fionda, Bruno
    Casa, Calogero
    Di Stefani, Alessandro
    Lancellotta, Valentina
    Placidi, Elisa
    Macchia, Gabriella
    Capocchiano, Nikola Dino
    Morganti, Alessio Giuseppe
    Kovacs, Gyorgy
    Bussu, Francesco
    Peris, Ketty
    Valentini, Vincenzo
    IN VIVO, 2021, 35 (04): : 2313 - 2319
  • [38] Radiation exposure to the kidney with interstitial iridium-192 high-dose-rate brachytherapy: Extent and rare morphologic changes of radiation nephropathy
    March, Christine
    Thormann, Maximilian
    Hass, Peter
    Seidensticker, Max
    Gross, Christian
    Omari, Jazan
    Pech, Maciej
    Damm, Robert
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (06) : 512 - 518
  • [39] Dose-volume impact in high-dose-rate iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer - a phase II study
    Pinkawa, M
    Fischedick, K
    Treusacher, P
    Asadpour, B
    Gagel, B
    Piroth, MD
    Borchers, H
    Jakse, G
    Eble, MJ
    RADIOTHERAPY AND ONCOLOGY, 2006, 78 (01) : 41 - 46
  • [40] TREATMENT OF SKIN CARCINOMAS BY VALENCIA APPLICATORS OF HIGH DOSE RATE BRACHYTHERAPY AND DERMOSCOPIC TUMORAL RESPONSE.
    Marin, A.
    Vargas-Diez, E.
    Cerezo, L.
    Garcia-Diez, A.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S225 - S225